Farid Keramati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Farid Keramati has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Hendrik G. Stunnenberg
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
4 shared publications Annemieke M. Peters van Ton
Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications- Ehsan Arefian
Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
2 shared publications Guus P. Leijte
Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publicationsHidde Heesakkers
Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publicationsInge Grondman
Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications
Latest Publications
- Open Access
Platform-Imprinted Transcriptional and Clonal Remodeling of αβ and γδT Cells After Allogeneic Transplantation
Immune reconstitution after allogeneic hematopoietic stem cell transplantation is influenced by graft-composition and viral reactivation, but the combined long-term impact on αβ and γδT cells remains unclear. We analyzed a cohort of 213 patients receiving either αβT cell-depleted grafts (n=146; graft engineering that removes donor αβT cells) or T cell-replete grafts (n=67; containing donor T cells). Longitudinal immune phenotyping was integrated with bulk and single-cell TCR repertoire and transcriptomic profiling. CMV reactivation was associated with expansion of CD8 + αβT cells across both transplant types and with numerical dominance of Vδ2 − γδT cells specifically in αβT cell-depleted recipients. Vδ2 − γδT cells underwent early polyclonal expansion followed by repertoire focusing, independent of CMV, whereas αβT cells remained clonally restricted. Reduced early Vδ2 + γδTCR diversity was associated with EBV reactivation. Single-cell and TCR tracking analyses revealed long-term persistence of donor-derived Vδ2 + γδTCRs, whereas Vδ1 + γδ and αβT cell repertoires were predominantly rebuilt de novo. Despite de novo rebuilding, αβTCR repertoire diversity diverged by platform at one year: αβT cell-depleted recipients exhibited marked (hyper)expansion of αβTCR clonotypes and lower diversity than T cell-replete recipients, indicating a durable imprint of graft engineering on αβTCR-clonality. Transcriptomic profiling showed that post-transplant T cells predominantly adopted effector programs, with platform-dependent polarization toward cytotoxic signatures in αβT cell–depleted recipients and toward AREG-associated tissue-repair signatures in T cell–replete recipients, consistent with wound-healing functions. In conclusion, transplantation platforms imprint durable clonal and transcriptional remodeling of αβ and γδT cells, while viral reactivation primarily amplifies expansion without fundamentally reshaping repertoire architecture. Abstract Figure:
Open AccessPlatform-Imprinted Transcriptional and Clonal Remodeling of αβ and γδT Cells After Allogeneic Transplantation
Immune reconstitution after allogeneic hematopoietic stem cell transplantation is influenced by graft-composition and viral reactivation, but the combined long-term impact on αβ and γδT cells remains unclear. We analyzed a cohort of 213 patients receiving either αβT cell-depleted grafts (n=146; graft engineering that removes donor αβT cells) or T cell-replete grafts (n=67; containing donor T cells). Longitudinal immune phenotyping was integrated with bulk and single-cell TCR repertoire and transcriptomic profiling. CMV reactivation was associated with expansion of CD8 + αβT cells across both transplant types and with numerical dominance of Vδ2 − γδT cells specifically in αβT cell-depleted recipients. Vδ2 − γδT cells underwent early polyclonal expansion followed by repertoire focusing, independent of CMV, whereas αβT cells remained clonally restricted. Reduced early Vδ2 + γδTCR diversity was associated with EBV reactivation. Single-cell and TCR tracking analyses revealed long-term persistence of donor-derived Vδ2 + γδTCRs, whereas Vδ1 + γδ and αβT cell repertoires were predominantly rebuilt de novo. Despite de novo rebuilding, αβTCR repertoire diversity diverged by platform at one year: αβT cell-depleted recipients exhibited marked (hyper)expansion of αβTCR clonotypes and lower diversity than T cell-replete recipients, indicating a durable imprint of graft engineering on αβTCR-clonality. Transcriptomic profiling showed that post-transplant T cells predominantly adopted effector programs, with platform-dependent polarization toward cytotoxic signatures in αβT cell–depleted recipients and toward AREG-associated tissue-repair signatures in T cell–replete recipients, consistent with wound-healing functions. In conclusion, transplantation platforms imprint durable clonal and transcriptional remodeling of αβ and γδT cells, while viral reactivation primarily amplifies expansion without fundamentally reshaping repertoire architecture. Abstract Figure:
- Open Access
- 18 April 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (5) , 737-747
Systemic inflammation impairs myelopoiesis and interferon type I responses in humans
Systemic inflammatory conditions are classically characterized by an acute hyperinflammatory phase, followed by a late immunosuppressive phase that elevates the susceptibility to secondary infections. Comprehensive mechanistic understanding of these phases is largely lacking. To address this gap, we leveraged a controlled, human in vivo model of lipopolysaccharide (LPS)-induced systemic inflammation encompassing both phases. Single-cell RNA sequencing during the acute hyperinflammatory phase identified an inflammatory CD163 + SLC39A8 + CALR + monocyte-like subset (infMono) at 4 h post-LPS administration. The late immunosuppressive phase was characterized by diminished expression of type I interferon (IFN)-responsive genes in monocytes, impaired myelopoiesis and a pronounced attenuation of the immune response on a secondary LPS challenge 1 week after the first. The infMono gene program and impaired myelopoiesis were also detected in patient cohorts with bacterial sepsis and coronavirus disease. IFNβ treatment restored type-I IFN responses and proinflammatory cytokine production and induced monocyte maturation, suggesting a potential treatment option for immunosuppression.
- 18 April 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (5) , 737-747
Open AccessSystemic inflammation impairs myelopoiesis and interferon type I responses in humans
Systemic inflammatory conditions are classically characterized by an acute hyperinflammatory phase, followed by a late immunosuppressive phase that elevates the susceptibility to secondary infections. Comprehensive mechanistic understanding of these phases is largely lacking. To address this gap, we leveraged a controlled, human in vivo model of lipopolysaccharide (LPS)-induced systemic inflammation encompassing both phases. Single-cell RNA sequencing during the acute hyperinflammatory phase identified an inflammatory CD163 + SLC39A8 + CALR + monocyte-like subset (infMono) at 4 h post-LPS administration. The late immunosuppressive phase was characterized by diminished expression of type I interferon (IFN)-responsive genes in monocytes, impaired myelopoiesis and a pronounced attenuation of the immune response on a secondary LPS challenge 1 week after the first. The infMono gene program and impaired myelopoiesis were also detected in patient cohorts with bacterial sepsis and coronavirus disease. IFNβ treatment restored type-I IFN responses and proinflammatory cytokine production and induced monocyte maturation, suggesting a potential treatment option for immunosuppression.
- Open Access
Systemic inflammation impairs human myelopoiesis and interferon I responses
Systemic inflammation (SI) plays a detrimental role in various conditions with high mortality rates 1–4 . SI manifests an acute hyperinflammation followed by long-lasting immunosuppression, increasing patients’ risks for secondary infections and impaired clinical outcomes 5–7 . Due to the extensive heterogeneity in SI etiology, the mechanisms governing these states are incompletely understood. Here, we characterized acute and late effects of lipopolysaccharide (LPS)-induced SI (LPS-SI 8 ) on blood monocytes and bone marrow (BM) cells of healthy volunteers. Like clinical SI, LPS administration elicited a profound but transient acute response. Single-cell transcriptomic analysis of acute LPS-SI unveiled loss of BM monocytes and appearance of an inflammatory monocyte-like (i-Mono’s) population, expressing gene programs similar to early-stage sepsis patients 9 . In the ensuing late phase of LPS-SI, we observed reduced expression of interferon type I (IFN-I) responsive genes in monocytes and profound attenuation of in vivo response to a second LPS challenge. Furthermore, late LPS-SI led to impaired myelopoiesis with a loss of intermediate and non-classical monocytes. In accordance, we show compromised myelopoiesis also occurs in late-stage sepsis. Finally, IFNβ treatment reversed LPS-induced immunosuppression in monocytes. Our results reveal long-lasting effects of SI on myelopoiesis and substantiate the importance of IFN-I in the pathophysiology of SI-induced immunosuppression.
Open AccessSystemic inflammation impairs human myelopoiesis and interferon I responses
Systemic inflammation (SI) plays a detrimental role in various conditions with high mortality rates 1–4 . SI manifests an acute hyperinflammation followed by long-lasting immunosuppression, increasing patients’ risks for secondary infections and impaired clinical outcomes 5–7 . Due to the extensive heterogeneity in SI etiology, the mechanisms governing these states are incompletely understood. Here, we characterized acute and late effects of lipopolysaccharide (LPS)-induced SI (LPS-SI 8 ) on blood monocytes and bone marrow (BM) cells of healthy volunteers. Like clinical SI, LPS administration elicited a profound but transient acute response. Single-cell transcriptomic analysis of acute LPS-SI unveiled loss of BM monocytes and appearance of an inflammatory monocyte-like (i-Mono’s) population, expressing gene programs similar to early-stage sepsis patients 9 . In the ensuing late phase of LPS-SI, we observed reduced expression of interferon type I (IFN-I) responsive genes in monocytes and profound attenuation of in vivo response to a second LPS challenge. Furthermore, late LPS-SI led to impaired myelopoiesis with a loss of intermediate and non-classical monocytes. In accordance, we show compromised myelopoiesis also occurs in late-stage sepsis. Finally, IFNβ treatment reversed LPS-induced immunosuppression in monocytes. Our results reveal long-lasting effects of SI on myelopoiesis and substantiate the importance of IFN-I in the pathophysiology of SI-induced immunosuppression.
- Open Access
- 8 April 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (7)
Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells
Chronic inflammation and immune dysfunction play a key role in the development of non-AIDS–related comorbidities. The aim of our study was to characterize the functional phenotype of immune cells in people living with HIV (PLHIV). We enrolled a cross-sectional cohort study of PLHIV on stable antiretroviral therapy and healthy controls. We assessed ex vivo cytokine production capacity and transcriptomics of monocytes and T cells upon bacterial, fungal, and viral stimulation. PLHIV exhibited an exacerbated proinflammatory profile in monocyte-derived cytokines, but not in lymphocyte-derived cytokines. Particularly, the production of the IL-1β to imiquimod, E . coli LPS, and Mycobacterium tuberculosis was increased, and this production correlated with plasma concentrations of high-sensitivity C-reactive protein and soluble CD14. This increase in monocyte responsiveness remained stable over time in subsequent blood sampling after more than 1 year. Transcriptome analyses confirmed priming of the monocyte IL-1β pathway, consistent with a monocyte-trained immunity phenotype. Increased plasma concentrations of β-glucan, a well-known inducer of trained immunity, were associated with increased innate cytokine responses. Monocytes of PLHIV exhibited a sustained proinflammatory immune phenotype with priming of the IL-1β pathway. Training of the innate immune system in PLHIV likely plays a role in long-term HIV complications and provides a promising therapeutic target for inflammation-related comorbidities.
- 8 April 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (7)
Open AccessChronic HIV infection induces transcriptional and functional reprogramming of innate immune cells
Chronic inflammation and immune dysfunction play a key role in the development of non-AIDS–related comorbidities. The aim of our study was to characterize the functional phenotype of immune cells in people living with HIV (PLHIV). We enrolled a cross-sectional cohort study of PLHIV on stable antiretroviral therapy and healthy controls. We assessed ex vivo cytokine production capacity and transcriptomics of monocytes and T cells upon bacterial, fungal, and viral stimulation. PLHIV exhibited an exacerbated proinflammatory profile in monocyte-derived cytokines, but not in lymphocyte-derived cytokines. Particularly, the production of the IL-1β to imiquimod, E . coli LPS, and Mycobacterium tuberculosis was increased, and this production correlated with plasma concentrations of high-sensitivity C-reactive protein and soluble CD14. This increase in monocyte responsiveness remained stable over time in subsequent blood sampling after more than 1 year. Transcriptome analyses confirmed priming of the monocyte IL-1β pathway, consistent with a monocyte-trained immunity phenotype. Increased plasma concentrations of β-glucan, a well-known inducer of trained immunity, were associated with increased innate cytokine responses. Monocytes of PLHIV exhibited a sustained proinflammatory immune phenotype with priming of the IL-1β pathway. Training of the innate immune system in PLHIV likely plays a role in long-term HIV complications and provides a promising therapeutic target for inflammation-related comorbidities.
- 5 May 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (10) , 7765-7774
MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells
Recent advances in small RNA research have implicated microRNAs (miRNAs) as important regulators of proliferation and development. The miR-371-373 cluster is prominently expressed in human embryonic stem cells (ESCs) and rapidly decreases after cell differentiation. MiR-371-373 cluster was investigated as one of the key factors of stem cell maintenance and pluripotency in unrestricted somatic stem cells (USSCs) using a lentivirus system. Gene expression showed a dual effect on proliferation, which revealed a transient cell cycle progression and consequent repression in pluripotency factors and cell cycle genes. Cell proliferation analysis with CFU, MTT, and DNA content assays further confirmed the dual effect of cluster after prolonged exposure. Analyzing the course of action, it seems that miR-371-373 cluster acts as an onco/tumor suppressor-miR. MiR371-373 cluster acts by modulating the function of these factors and limiting the excessive cell cycle propagation upon oncogenic stimuli to protect cells from replicative stress, but also activate CDK inhibitors and transcriptional repressors of the retinoblastoma family to cause cell cycle arrest. In contrast to the previous studies, we believe that miR-371-373 cluster functions as a self-renewal miRNA to induce and maintain the pluripotent state but also to potentially inhibit dysregulated proliferation through cell cycle arrest. It seems that miR-371-373 cluster presents with a dual effect in this cellular context which may possess different actions in various cells. This not only expands the basic knowledge of the cluster but may offer a great chance for therapeutic interventions.
- 5 May 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (10) , 7765-7774
MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells
Recent advances in small RNA research have implicated microRNAs (miRNAs) as important regulators of proliferation and development. The miR-371-373 cluster is prominently expressed in human embryonic stem cells (ESCs) and rapidly decreases after cell differentiation. MiR-371-373 cluster was investigated as one of the key factors of stem cell maintenance and pluripotency in unrestricted somatic stem cells (USSCs) using a lentivirus system. Gene expression showed a dual effect on proliferation, which revealed a transient cell cycle progression and consequent repression in pluripotency factors and cell cycle genes. Cell proliferation analysis with CFU, MTT, and DNA content assays further confirmed the dual effect of cluster after prolonged exposure. Analyzing the course of action, it seems that miR-371-373 cluster acts as an onco/tumor suppressor-miR. MiR371-373 cluster acts by modulating the function of these factors and limiting the excessive cell cycle propagation upon oncogenic stimuli to protect cells from replicative stress, but also activate CDK inhibitors and transcriptional repressors of the retinoblastoma family to cause cell cycle arrest. In contrast to the previous studies, we believe that miR-371-373 cluster functions as a self-renewal miRNA to induce and maintain the pluripotent state but also to potentially inhibit dysregulated proliferation through cell cycle arrest. It seems that miR-371-373 cluster presents with a dual effect in this cellular context which may possess different actions in various cells. This not only expands the basic knowledge of the cluster but may offer a great chance for therapeutic interventions.
- Open Access
- 1 January 2015
- Published by ScopeMed in Stem Cell Fundamentals and Practice
- Vol. 1 (1) , 1
Running the differentiation program by transcription factor decoys in stem cells
- 1 January 2015
- Published by ScopeMed in Stem Cell Fundamentals and Practice
- Vol. 1 (1) , 1
Open AccessRunning the differentiation program by transcription factor decoys in stem cells